BOSTON, April 8, 2015 /PRNewswire/ -- PAREXEL
International Corporation (NASDAQ: PRXL), a leading global
biopharmaceutical services provider, today announced three new
academic programs at the PAREXEL Academy. The offerings span the
globe and are designed to prepare students for careers in the
biopharmaceutical industry:
- Bachelor of Science Degree in Clinical Research –
Offered in partnership with the Medical School Berlin, in
Berlin, Germany, the degree
program features courses specific to clinical research. Courses
range from ethics in health and medicine to conducting clinical
trials. Several courses are taught by PAREXEL experts.
- Postgraduate Certificate in Clinical Trial Management –
In cooperation with Salem State University in Salem, Massachusetts, the postgraduate
certificate program features a broad-based curriculum in various
components of the full life cycle of drug development.
- Joint Program for Clinical Research and Clinical Trial
Management – In collaboration with Kyoto Pharmaceutical
University in Kyoto, Japan, the
joint program provides fifth grade undergraduate students an
introductory, seven-week course in clinical research and clinical
trial management.
"PAREXEL is committed to developing the biopharmaceutical
industry's next-generation global workforce," said Heidrun Bruchmann, Ph.D., Senior Director,
PAREXEL Academy. "Through the PAREXEL Academy, we tailor
educational and degree programs with our partners to equip the
future health sciences workforce with a holistic and
cross-functional foundation in clinical research and clinical trial
management."
For more than a decade, the PAREXEL Academy has designed and
implemented a wide range of learning programs tailored to enable
clinical research management practices for learners inside and
outside of PAREXEL. The PAREXEL Academy has locations in
the United States, Europe, and Asia. Since inception,
approximately 1,000 students have graduated from the Academy's
programs, including its undergraduate Bachelor of Science
program.
Mary L. Churchill, Ph.D.
Associate Provost, Innovation and Partnerships, Salem State
University, commented that, "Salem
State is committed to providing students with programs that
are both foundational and workforce-aligned. Through our
partnership with the PAREXEL Academy, we create programs to give
students the specific tools needed to succeed post-graduation in
biopharmaceutical research."
About PAREXEL International
PAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of expertise-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston, Massachusetts, PAREXEL operates in 81
locations in 51 countries around the world, and has approximately
16,530 employees. For more information about PAREXEL
International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its
affiliates.
This release contains "forward-looking" statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ materially from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from restructurings; the loss, modification,
or delay of contracts which would, among other things, adversely
impact the Company's recognition of revenue included in backlog;
the Company's dependence on certain industries and clients; the
Company's ability to win new business, manage growth and costs, and
attract and retain employees; the Company's ability to complete
additional acquisitions, and to integrate newly acquired businesses
including the acquisition of ClinIntel Limited, or enter into new
lines of business; the impact on the Company's business of
government regulation of the drug, medical device and
biotechnology industry; consolidation within the pharmaceutical
industry and competition within the biopharmaceutical services
industry; the potential for significant liability to clients and
third parties; the potential adverse impact of health care reform;
and the effects of foreign currency exchange rate fluctuations and
other international economic, political, and other
risks. Such factors and others are discussed more fully
in the section entitled "Risk Factors" of the Company's Quarterly
Report on Form 10-Q for the quarter ended December 31,
2015 as filed with the Securities and Exchange Commission
on February 5, 2015, which "Risk Factors" discussion is
incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin, PAREXEL
International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com
Cristi Barnett, PAREXEL
International
Tel.: +1 781-434-4019
Email: Cristi.Barnett@PAREXEL.com
Matthew Briggs, PAN
Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/parexel-strengthens-commitment-to-global-biopharmaceutical-workforce-with-new-parexel-academy-programs-300061722.html
SOURCE PAREXEL International Corporation